Day 1 :
Keynote Forum
Heyam Saad Ali
Dubai Pharmacy College, UAE
Keynote: Factors affecting oral bioavailability
Time : 10:00-11:00
Biography:
Heyam S. Ali is a Professor in Dubai Pharmacy College, Prof. Heyam Saad Ali has completed her PhD from Bradford University, UK. She is
Head of Pharmaceutics Department, Dubai Pharmacy College, UAE. She has teaching and research experience of about 25 years. She has
published more than 44 papers in reputed journals and has been serving as an editorial board member of several pharmaceutical Journals.
Abstract:
During the early sixties, drug product development was at its peak and soon afterwards, many new products were introduced. Some of these new chemical compounds exhibited variations in their pharmacologic and therapeutic activity This led to the recognition of the fact that a great deal of knowledge is required for studying the many factors that affect the bioavailability of the administered drug. The term bioavailability is defined as the rate and extent of the active ingredient (s) in the biological system. This movement of the drug is influenced by many factors such as including routes of administration, physicochemical drug properties, physiological factors, methods & techniques used in manufacture, the dosage form into which the drug incorporated and the excipients such as bulking agents, binders, lubricants, dyes, disintegrants, coating materials, etc.). Hence these factors may require special consideration in determining bioavailability of the
active ingredient from the dosage form.
During the early sixties, drug product development was at its peak and soon afterwards, many new products were introduced. Some of these new chemical compounds exhibited variations in their pharmacologic and therapeutic activity This led to the recognition of the fact that a great deal of knowledge is required for studying the many factors that affect the bioavailability of the administered drug. The term bioavailability is defined as the rate and extent of the active ingredient (s) in the biological system. This movement of the drug is influenced by many factors such as including routes of administration, physicochemical drug properties, physiological factors, methods & techniques used in manufacture, the dosage form into which the drug incorporated and the excipients such as bulking agents, binders, lubricants, dyes, disintegrants, coating materials, etc.). Hence these factors may require special consideration in determining bioavailability of the active ingredient from the dosage form.
- Workshop
Session Introduction
Royida Al Marastani
SEHA-Ambulatory Healthcare Services, UAE
Title: Drug interactions affecting drug bioavailability
Biography:
Royida Al Marastani is a senior pharmacist with more than thirty years of experience in the UAE in Abu Dhabi in Primary Health Centers (PHC), Urgent Care Center (UCC), Ambulatory Health Services (AHS) and MSc in Clinical Pharmacy UK. A lecturer from 2003 in Ministry of Health (MOH), in CPE/CME pharmacist’s program from 2011 in SEHA/ Ambulatory Healthcare Services (AHS). Conducting research, conference abstracts, invited presentations in the national & international conferences, focusing on pharmaceutical care based on safety and efficacy of the medications.
Abstract:
Drug-drug interactions (DDIs) are increased especially with polypharmacy patients leading to increased or decreased the clinical efficacy or increased the risk of the side effects or even the toxic effects.DDI can be classify into two classes pharmacokinetic and pharmacodynamic which affects the bioavailability of the drugs
Example 1:
H2 antagonists (e.g.ranitidine), antacids (e.g., aluminium hydroxide and sodium bicarbonate) and PPI (e.g., omeprazole, esomeprazole, pantoprazole) that increase the gastric pH lead to facilitate the absorption of beta-blockers .
Example 2:
Antifungal agents (e.g., ketoconazole or itraconazole), requires an acidic environment, therefore, their co-administration with drugs able to increase gastric pH, may cause a decrease in both dissolution and absorption of antifungal drugs. Therefore, antacid or anticholinergics, or PPI might be administered at least 2 h after the administration of antifungal agents.
Example 3:
The administration of drugs able to increase the gastric pH with ampicillin, atazanavir, clopidogrel, diazepam, methotrexate, vitamin B12, paroxetine and raltegravir are not recommended.
Example 4:
The administration of drugs that decrease the gastric pH (e.g., pentagastrin), may have an opposite effect.
Example 5:
Tetracyclines (e.g., doxycycline or minocycline) in the digestive tract can combine with metal ions (e.g., calcium, magnesium, aluminum, iron) to form complexes poorly absorbed. Consequently certain drugs (e.g., antacids, preparations containing magnesium salts, aluminum and calcium preparations containing iron) can significantly reduce the tetracyclines absorption.
Example 6:
Antacids reduce the absorption of fluoroquinolones (e.g., ciprofloxacin), penicillamines and tetracyclines, because the metal ions form complexes with the drug. So antacids and fluoroquinolones should be administered at least 2 h apart or more.
Example 7:
Metoclopramide, may accelerate gastric emptying, hence decreasing the absorption of digoxin and theophylline whereas it can accelerate the absorption of alcohol, acetylsalicylic acid, acetaminophen, tetracycline and levo-dopa.
- Clinical Research | Drug Discovery | Pharmacology | Pharmaceutical Formulations
Chair
Heyam Saad Ali
Dubai Pharmacy College, UAE
Co-Chair
Sudhir Kumar Sharma
New York University Abu Dhabi, UAE
Session Introduction
Sudhir Kumar Sharma
New York University Abu Dhabi, UAE
Title: Synthesis of Naproxen molecular clusters by super-critical CO2 processing
Biography:
Sudhir Kumar Sharma has completed his Masters in Physics and MTech in Materials from Department of Physics, Barkatullah University Bhopal, India. He has completed his PhD from the Indian Institute of Science Bangalore, India. He as a Post-doctratral Fellow attended Centre for Nano Science and Engineering (CeNSE), IISc. Bangalore, India. He has worked as a Research Associate at New York University Abu Dhabi, UAE and is currently working as a Research Scientist. He has more than 90 international journals and conferences publications
Abstract:
In pharmaceutical industry, poor water solubility and limited bioavailability has a major concern on new drug development. It is well established that the bioavailability of such drugs can be improved by reducing their particle size. A number of conventional strategies are available in literature for particle size reduction but they suffer with some disadvantages and handling concerns. Recently, supercritical CO2 (sc-CO2) based processes are found to be more promising for micronization of pharmaceuticals as they have successfully addressed the above concerns and offer additional advantages like economic, non-toxic, scalable, environmentally compatible and etc. In present studies, we report the synthesis of naproxen molecular clusters via supercritical CO2 drug formulation. These molecular clusters were collected in a special designed a two-stage collection vessel, cooled to liquid N2 temperatures, resulted embedding of drug molecular clusters in ‘dry ice’. Gradual transferring of the ‘dry ice’ into deionized water, resulted in the true solubilization of drug molecular clusters. Afterword’s, these solutions were drop-casted on silicon substrate and dried for overnight under ambient conditions, resulted in a stable, viscous films with liquid like behavior. Analytical characterizations showed that these solutions have retained their chemical and structural identity after sc-CO2 processing. This is interesting to note that raw naproxen powder is solid powder under ambient conditions with melting points of 154o C. Our observations are expected to explore the sc-CO2 processing strategy for other existing drug formulations and would open up new drug delivery platforms.
Amal Ahmed Abdel Nabbi Hassan
Dubai Pharmacy College, UAE
Title: The effect of mucoadhesive polymers in improving drug bioavailability & absorption
Biography:
Dr.Amal Ahmed Abdel nabbi Hassan, Dubai Pharmacy College, Dubai, UAE. . She has teaching research experience and high communication skills. She has been serving as an OCM and participating in many international conferences
Abstract:
The oral mucosa offers an interesting site for the application of dosage forms that release drugs within/throughout the oral mucosa, by assuring a high drug bioavailability for topic and systemic effects. The mucoadhesion is a complex phenomenon and the mucoadhesive bond consists of two different parts, the mucoadhesive polymers and the mucous substrate. In addition to factors related to the oral mucosa and oral environment features, the physical-chemical characteristics of mucoadhesive polymers must be also considered as factors influencing the mucoadhesive bonds
The study was conducted to formulate different types of MDDS, using mucoadhesive polymers (e.g. carbopols, sodium alginate, chitosan…) and have been utilized in different dosage forms in efforts to achieve systemic delivery of drugs through mucosal membrane.
Conclusion: Since a sustained drug release can be guaranteed only if dosage forms remain in contact with the oral site of absorption/application for a prolonged time, the development of mucoadhesive dosage forms is mandatory. They can prolong the residence time of the dosage form at the site of absorption thus enhance drug therapeutic efficacy.
Said Abdel Karim Abdel Hamid Mohamed
SEHA-Ambulatory Healthcare Services, UAE
Title: Gene therapy and it’s recent application
Biography:
Said is working as a clinical staff lead pharmacist with more than 8 years of experience as Hospital pharmacist, furthermore he worked as a Teaching Aids at Al Ahram Canadian university Egypt, as well as drug control specialist in antibiotics department at NODCAR (the national organization for drug control & research) currently he is working as pharmacist lead in Ambulatory Healthcare Services-SEHA, Participated in many local and international conferences, Said has certified as American board pharmacotherapy specialist (BCPS). He got his M.Sc. in clinical pharmacy in 2014 and in 2015 got his MBA from Torrens university/Abu Dhabi.
Abstract:
Gene therapy is one of the most advanced ways in threatening the most untreatable diseases and its simply when DNA is introduced into a patient to treat a genetic disease. The new DNA usually contains a functioning gene to correct the effects of a disease-causing mutation. Sometimes the whole or part of a gene is defective or missing from birth or a gene can change or mutate during adult life. Any of these variations can disrupt how proteins are made, which can contribute to health problems or diseases. In this presentation we will illustrate the basics of gene therapy and the most recent approved gene therapy products.
Rahul A Hajare
Indian Council of Medical Research, India
Title: Fact file of Levofloxacin and risk factors of OH affiliated matrix impurity, disregards impurity and specified impurity associated undetectable impurity an extended study of second generation antibiotics
Biography:
Rahul A Hajare is Fellow of Indian Council of Medical Research, New Delhi, India. He is PhD student of reputed University Vinayaka Mission Research Foundation, Salem, Tamil Nadu. He is a winner of World Academic Championship-2017 in Pharmacy (Antiretroviral Therapy). He is among world's 500 most influential experts in pharmacy for the year 2017 on earth. He is also an alumni of The Yoga Institute Centenary Celebration Mumbai.
Abstract:
To highlight this important part of the research process, we asked research scientists to speak about their own experiences with failure. Research scientist explains why considers non-significant and negative studies to be important parts of publication history. Licensed data by USFDA Levofloxacin, but pregnancy category risk not ruled out. Levofloxacin identified by IUPAC (3S)-9-Fluor-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]chinolin-6-carbonsäure, by the end of 6-carboxylic acid group. Legal status is general prescription only. Levofloxacin was approved for medical use in the United States in 1996. It is on the world health organization's list of essential medicines, the most effective and safe medicines needed in a health system. It is available as a generic medication. The wholesale cost in the developing world is about 0.44 to 0.95 USD per week of treatment. In the United States a week of treatment costs about 50 to 100 USD. As of 2016, the US Food and Drug Administration (FDA) recommended that "serious side effects associated with OH side antibacterial drugs generally outweigh the benefits for patients with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections who have other treatment options. For patients with these conditions, OH should be inherent impurity seen in levofloxacin. Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic. It is used to treat a number of bacterial infection including acute bacterial, sinusitis, Pneumonia and urinary infection, chronic prostatitis.